Загрузка...
Epigenetic Therapies in MDS and AML
The use of low dose hypomethylating agents for patients with myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia (AML) has had made a significant impact. In the past, therapies for these diseases were limited and patients who elected to receive treatment were subject to highly toxic,...
Сохранить в:
Главные авторы: | , |
---|---|
Формат: | Artigo |
Язык: | Inglês |
Опубликовано: |
2013
|
Предметы: | |
Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4086806/ https://ncbi.nlm.nih.gov/pubmed/22956506 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/978-1-4419-9967-2_13 |
Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|